Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Correspondence on the debate regarding the haemodynamic definition of pulmonary hypertension.

Maron BA, Choudhary G, Tedford RJ, Brittain E.

Eur Respir J. 2019 Jun 5;53(6). pii: 1900727. doi: 10.1183/13993003.00727-2019. Print 2019 Jun. No abstract available.

PMID:
31167886
2.

Toward Early Diagnosis of Pulmonary Hypertension: Lessons From Oz.

Maron BA, Wertheim BM.

J Am Coll Cardiol. 2019 Jun 4;73(21):2673-2675. doi: 10.1016/j.jacc.2019.03.473. No abstract available.

PMID:
31146811
3.

Back to the Future: Building Up the Case for Exploring Red Blood Cell Morphology in Pulmonary Arterial Hypertension.

Maron BA.

Ann Am Thorac Soc. 2019 May;16(5):548-550. doi: 10.1513/AnnalsATS.201901-043ED. No abstract available.

PMID:
31042093
4.

Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction Patients: Where to Draw the Line.

Simon MA, Maron BA.

Am J Respir Crit Care Med. 2019 Apr 30. doi: 10.1164/rccm.201903-0689ED. [Epub ahead of print] No abstract available.

PMID:
31038986
5.

Multisystem Healthcare Use among U.S. Veterans with Pulmonary Hypertension.

Gillmeyer KR, Lee KM, Shao Q, Miller DR, Maron BA, Klings ES, Rinne ST, Wiener RS.

Ann Am Thorac Soc. 2019 Apr 26. doi: 10.1513/AnnalsATS.201902-109RL. [Epub ahead of print] No abstract available.

PMID:
31026406
6.

Moving Beyond the Sarcomere to Explain Heterogeneity in Hypertrophic Cardiomyopathy: JACC Review Topic of the Week.

Maron BJ, Maron MS, Maron BA, Loscalzo J.

J Am Coll Cardiol. 2019 Apr 23;73(15):1978-1986. doi: 10.1016/j.jacc.2019.01.061. Review.

PMID:
31000001
7.

A Concerning Trend for Patients With Pulmonary Hypertension in the Era of Evidence-Based Medicine.

Maron BA, Ryan JJ.

Circulation. 2019 Apr 16;139(16):1861-1864. doi: 10.1161/CIRCULATIONAHA.118.037613. No abstract available.

PMID:
30986105
8.

Precision Medicine in Pulmonary Arterial Hypertension.

Leopold JA, Maron BA.

Circ Res. 2019 Mar 15;124(6):832-833. doi: 10.1161/CIRCRESAHA.119.314757. No abstract available.

PMID:
30870130
9.

Isolating pulmonary microvascular endothelial cells ex vivo: Implications for pulmonary arterial hypertension, and a caution on the use of commercial biomaterials.

Wertheim BM, Lin YD, Zhang YY, Samokhin AO, Alba GA, Arons E, Yu PB, Maron BA.

PLoS One. 2019 Feb 27;14(2):e0211909. doi: 10.1371/journal.pone.0211909. eCollection 2019.

10.

TORward a Molecular Convergence Point in Pulmonary Arterial Hypertension With mTOR.

Maron BA, Wilkins MR.

JACC Basic Transl Sci. 2018 Dec 31;3(6):763-765. doi: 10.1016/j.jacbts.2018.08.003. eCollection 2018 Dec. No abstract available.

11.

Mild Pulmonary Hypertension Is Associated With Increased Mortality: A Systematic Review and Meta-Analysis.

Kolte D, Lakshmanan S, Jankowich MD, Brittain EL, Maron BA, Choudhary G.

J Am Heart Assoc. 2018 Sep 18;7(18):e009729. doi: 10.1161/JAHA.118.009729.

12.

Pulmonary Vascular Disease Across the Life Span: A Call for Bridging Pediatric and Adult Cardiopulmonary Research and Care.

Abman SH, Lovering AT, Maron BA.

Am J Respir Crit Care Med. 2018 Jul 18. doi: 10.1164/rccm.201807-1240ED. [Epub ahead of print] No abstract available.

PMID:
30020807
13.

NEDD9 targets COL3A1 to promote endothelial fibrosis and pulmonary arterial hypertension.

Samokhin AO, Stephens T, Wertheim BM, Wang RS, Vargas SO, Yung LM, Cao M, Brown M, Arons E, Dieffenbach PB, Fewell JG, Matar M, Bowman FP, Haley KJ, Alba GA, Marino SM, Kumar R, Rosas IO, Waxman AB, Oldham WM, Khanna D, Graham BB, Seo S, Gladyshev VN, Yu PB, Fredenburgh LE, Loscalzo J, Leopold JA, Maron BA.

Sci Transl Med. 2018 Jun 13;10(445). pii: eaap7294. doi: 10.1126/scitranslmed.aap7294.

14.

Pulmonary Hypertension: Good Intentions, But a Questionable Approach.

Leary PJ, Maron BA, Tedford RJ, Lahm T.

Ann Am Thorac Soc. 2018 Jun;15(6):664-666. doi: 10.1513/AnnalsATS.201803-197ED. No abstract available.

PMID:
29856254
15.

Reply: Can treprostinil-induced early gastrointestinal side effects serve as predictors of pulmonary arterial hypertension prognosis?

Leary PJ, Kolb TM, Maron BA, Tedford RJ, Zamanian RT.

Int J Cardiol. 2018 Aug 1;264:188. doi: 10.1016/j.ijcard.2018.03.130. No abstract available.

PMID:
29776569
16.

MicroRNA Dysregulation in Pulmonary Arteries from Chronic Obstructive Pulmonary Disease. Relationships with Vascular Remodeling.

Musri MM, Coll-Bonfill N, Maron BA, Peinado VI, Wang RS, Altirriba J, Blanco I, Oldham WM, Tura-Ceide O, García-Lucio J, de la Cruz-Thea B, Meister G, Loscalzo J, Barberà JA.

Am J Respir Cell Mol Biol. 2018 Oct;59(4):490-499. doi: 10.1165/rcmb.2017-0040OC.

PMID:
29757677
17.

Career Development of Young Physician-Scientists in the Cardiovascular Sciences: Perspective and Advice From the Early Career Committee of the Cardiopulmonary, Critical Care, and Resuscitation Council of the American Heart Association.

Agarwal S, Spiekerkoetter E, Austin ED, de Jesus Perez V, Dezfulian C, Maron BA, Ryan JJ, Starks MA, Yu PB, Bonnet S, Perman SM.

Circ Res. 2018 May 11;122(10):1330-1333. doi: 10.1161/CIRCRESAHA.118.312999. No abstract available.

18.

Association between Pulmonary Hypertension and Clinical Outcomes in Hospitalized Patients with Sickle Cell Disease.

Agarwal MA, Shah M, Patel B, Nolan VG, Reed GL, Oudiz RJ, Choudhary G, Maron BA.

Am J Respir Crit Care Med. 2018 Aug 15;198(4):534-537. doi: 10.1164/rccm.201802-0261LE. No abstract available.

PMID:
29648884
19.

Update in Pulmonary Vascular Disease 2016 and 2017.

Brittain EL, Thennapan T, Maron BA, Chan SY, Austin ED, Spiekerkoetter E, Bogaard HJ, Guignabert C, Paulin R, Machado RF, Yu PB.

Am J Respir Crit Care Med. 2018 Jul 1;198(1):13-23. doi: 10.1164/rccm.201801-0062UP. No abstract available.

PMID:
29533671
20.

Segmental Arterial Mediolysis: An Important but Often Overlooked Cause of Multi-Vessel Thrombosis.

Carroll BJ, Steigner ML, Priya S, Bhatt DL, Maron BA.

Am J Med. 2018 Jun;131(6):e231-e234. doi: 10.1016/j.amjmed.2018.01.057. Epub 2018 Mar 2. No abstract available.

PMID:
29505754
21.

Network Analysis to Risk Stratify Patients With Exercise Intolerance.

Oldham WM, Oliveira RKF, Wang RS, Opotowsky AR, Rubins DM, Hainer J, Wertheim BM, Alba GA, Choudhary G, Tornyos A, MacRae CA, Loscalzo J, Leopold JA, Waxman AB, Olschewski H, Kovacs G, Systrom DM, Maron BA.

Circ Res. 2018 Mar 16;122(6):864-876. doi: 10.1161/CIRCRESAHA.117.312482. Epub 2018 Feb 5.

22.

H2 Receptor Antagonist Use and Mortality in Pulmonary Hypertension: Insight from the VA-CART Program.

Leary PJ, Hess E, Barón AE, Branch KR, Choudhary G, Hough CL, Maron BA, Ralph DD, Ryan JJ, Tedford RJ, Weiss NS, Zamanian RT, Lahm T.

Am J Respir Crit Care Med. 2018 Jun 15;197(12):1638-1641. doi: 10.1164/rccm.201801-0048LE. No abstract available.

23.

Redefining pulmonary hypertension.

Maron BA, Brittain EL, Choudhary G, Gladwin MT.

Lancet Respir Med. 2018 Mar;6(3):168-170. doi: 10.1016/S2213-2600(17)30498-8. Epub 2017 Dec 18. No abstract available.

PMID:
29269004
24.

Under Pressure to Clarify Pulmonary Hypertension Clinical Risk.

Maron BA, Wertheim BM, Gladwin MT.

Am J Respir Crit Care Med. 2018 Feb 15;197(4):423-426. doi: 10.1164/rccm.201711-2306ED. No abstract available.

25.

Systems Biology Approaches to Redox Metabolism in Stress and Disease States.

Wang RS, Oldham WM, Maron BA, Loscalzo J.

Antioxid Redox Signal. 2018 Oct 1;29(10):953-972. doi: 10.1089/ars.2017.7256. Epub 2017 Dec 20.

PMID:
29121773
26.

Sex-based differences in veterans with pulmonary hypertension: Results from the veterans affairs-clinical assessment reporting and tracking database.

Ventetuolo CE, Hess E, Austin ED, Barón AE, Klinger JR, Lahm T, Maddox TM, Plomondon ME, Thompson L, Zamanian RT, Choudhary G, Maron BA.

PLoS One. 2017 Nov 9;12(11):e0187734. doi: 10.1371/journal.pone.0187734. eCollection 2017.

27.

PVDOMICS: A Multi-Center Study to Improve Understanding of Pulmonary Vascular Disease Through Phenomics.

Hemnes AR, Beck GJ, Newman JH, Abidov A, Aldred MA, Barnard J, Berman Rosenzweig E, Borlaug BA, Chung WK, Comhair SAA, Erzurum SC, Frantz RP, Gray MP, Grunig G, Hassoun PM, Hill NS, Horn EM, Hu B, Lempel JK, Maron BA, Mathai SC, Olman MA, Rischard FP, Systrom DM, Tang WHW, Waxman AB, Xiao L, Yuan JX, Leopold JA; PVDOMICS Study Group.

Circ Res. 2017 Oct 27;121(10):1136-1139. doi: 10.1161/CIRCRESAHA.117.311737. No abstract available.

28.

Prognostic Effect and Longitudinal Hemodynamic Assessment of Borderline Pulmonary Hypertension.

Assad TR, Maron BA, Robbins IM, Xu M, Huang S, Harrell FE, Farber-Eger EH, Wells QS, Choudhary G, Hemnes AR, Brittain EL.

JAMA Cardiol. 2017 Dec 1;2(12):1361-1368. doi: 10.1001/jamacardio.2017.3882.

29.

Systems biology: An emerging strategy for discovering novel pathogenetic mechanisms that promote cardiovascular disease.

Maron BA, Leopold JA.

Glob Cardiol Sci Pract. 2016 Sep 30;2016(3):e201627. doi: 10.21542/gcsp.2016.27. Review.

30.

Functional impact of exercise pulmonary hypertension in patients with borderline resting pulmonary arterial pressure.

Oliveira RKF, Faria-Urbina M, Maron BA, Santos M, Waxman AB, Systrom DM.

Pulm Circ. 2017 Jul-Sep;7(3):654-665. doi: 10.1177/2045893217709025. Epub 2017 Jun 8.

31.

Thermodilution vs Estimated Fick Cardiac Output Measurement in Clinical Practice: An Analysis of Mortality From the Veterans Affairs Clinical Assessment, Reporting, and Tracking (VA CART) Program and Vanderbilt University.

Opotowsky AR, Hess E, Maron BA, Brittain EL, Barón AE, Maddox TM, Alshawabkeh LI, Wertheim BM, Xu M, Assad TR, Rich JD, Choudhary G, Tedford RJ.

JAMA Cardiol. 2017 Oct 1;2(10):1090-1099. doi: 10.1001/jamacardio.2017.2945.

32.

Hemodynamic and metabolic characteristics associated with development of a right ventricular outflow tract pressure gradient during upright exercise.

van Riel ACMJ, Systrom DM, Oliveira RKF, Landzberg MJ, Mulder BJM, Bouma BJ, Maron BA, Shah AM, Waxman AB, Opotowsky AR.

PLoS One. 2017 Jun 21;12(6):e0179053. doi: 10.1371/journal.pone.0179053. eCollection 2017.

33.

What's in a side effect? The association between pulmonary vasodilator adverse drug events and clinical outcomes in patients with pulmonary arterial hypertension.

Leary PJ, Kang S, Kolb TM, Maron BA, Ralph DD, Rao Y, Tedford RJ, Zamanian RT.

Int J Cardiol. 2017 Aug 1;240:386-391. doi: 10.1016/j.ijcard.2017.04.016. Epub 2017 Apr 6.

PMID:
28412029
34.

Mechanism of Progressive Heart Failure and Significance of Pulmonary Hypertension in Obstructive Hypertrophic Cardiomyopathy.

Covella M, Rowin EJ, Hill NS, Preston IR, Milan A, Opotowsky AR, Maron BJ, Maron MS, Maron BA.

Circ Heart Fail. 2017 Apr;10(4):e003689. doi: 10.1161/CIRCHEARTFAILURE.116.003689.

35.

Development of a Right Ventricular Outflow Tract Gradient During Upright Exercise: A Hemodynamic Observation.

van Riel AC, Systrom DM, Oliveira RK, Landzberg MJ, Mulder BJ, Bouma BJ, Maron BA, Shah AM, Waxman AB, Opotowsky AR.

J Am Coll Cardiol. 2017 Feb 7;69(5):595-597. doi: 10.1016/j.jacc.2016.11.039. No abstract available.

36.

Treatment differences in pulmonary arterial hypertension management.

Maron BA, Ryan JJ.

Pulm Circ. 2016 Dec;6(4):619. doi: 10.1086/688909. No abstract available.

37.

Pulmonary vascular and ventricular dysfunction in the susceptible patient (2015 Grover Conference series).

Maron BA, Machado RF, Shimoda L.

Pulm Circ. 2016 Dec;6(4):426-438. doi: 10.1086/688315. Review. Erratum in: Pulm Circ. 2017 Apr-Jun;7(2):559.

38.

Pulmonary Arterial Compliance in Acute Respiratory Distress Syndrome: Clinical Determinants and Association With Outcome From the Fluid and Catheter Treatment Trial Cohort.

Metkus TS, Tampakakis E, Mullin CJ, Houston BA, Kolb TM, Mathai SC, Damico R, Maron BA, Hassoun PM, Brower RG, Tedford RJ.

Crit Care Med. 2017 Mar;45(3):422-429. doi: 10.1097/CCM.0000000000002186.

39.

Translational Advances in the Field of Pulmonary Hypertension. Focusing on Developmental Origins and Disease Inception for the Prevention of Pulmonary Hypertension.

Maron BA, Abman SH.

Am J Respir Crit Care Med. 2017 Feb 1;195(3):292-301. doi: 10.1164/rccm.201604-0882PP. Review. No abstract available.

40.

Diagnosis, Treatment, and Clinical Management of Pulmonary Arterial Hypertension in the Contemporary Era: A Review.

Maron BA, Galiè N.

JAMA Cardiol. 2016 Dec 1;1(9):1056-1065. doi: 10.1001/jamacardio.2016.4471.

41.

Revisiting Athlete's Heart Versus Pathologic Hypertrophy: ARVC and the Right Ventricle.

Maron BJ, Maron BA.

JACC Cardiovasc Imaging. 2017 Apr;10(4):394-397. doi: 10.1016/j.jcmg.2016.05.011. Epub 2016 Aug 17. No abstract available.

42.

Genetic Misdiagnoses and the Potential for Health Disparities.

Manrai AK, Funke BH, Rehm HL, Olesen MS, Maron BA, Szolovits P, Margulies DM, Loscalzo J, Kohane IS.

N Engl J Med. 2016 Aug 18;375(7):655-65. doi: 10.1056/NEJMsa1507092.

43.

Update in Pulmonary Vascular Disease 2015.

Maron BA, Gladwin MT, Simon MA.

Am J Respir Crit Care Med. 2016 Jun 15;193(12):1337-44. doi: 10.1164/rccm.201601-0143UP. Review. No abstract available.

44.

Molecular Mechanisms of Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension.

Leopold JA, Maron BA.

Int J Mol Sci. 2016 May 18;17(5). pii: E761. doi: 10.3390/ijms17050761. Review.

45.

Death or Severe Injury at the Ball Game.

Zonfrillo MR, Janigian NG, Maron BA.

Curr Sports Med Rep. 2016 May-Jun;15(3):132-3. doi: 10.1249/JSR.0000000000000256. No abstract available.

46.

Independence Day: Separating Right Ventricular Function From Pulmonary Arterial Hypertension in Systemic Sclerosis.

Maron BA.

Circulation. 2016 Jun 14;133(24):2345-7. doi: 10.1161/CIRCULATIONAHA.116.023237. Epub 2016 May 11. No abstract available.

47.

Intratracheal Gene Delivery of SERCA2a Ameliorates Chronic Post-Capillary Pulmonary Hypertension: A Large Animal Model.

Aguero J, Ishikawa K, Hadri L, Santos-Gallego CG, Fish KM, Kohlbrenner E, Hammoudi N, Kho C, Lee A, Ibáñez B, García-Alvarez A, Zsebo K, Maron BA, Plataki M, Fuster V, Leopold JA, Hajjar RJ.

J Am Coll Cardiol. 2016 May 3;67(17):2032-46. doi: 10.1016/j.jacc.2016.02.049.

48.

Relation of Doppler Tissue Imaging Parameters With Heart Failure Progression in Hypertrophic Cardiomyopathy.

Kalra A, Harris KM, Maron BA, Maron MS, Garberich RF, Haas TS, Lesser JR, Maron BJ.

Am J Cardiol. 2016 Jun 1;117(11):1808-14. doi: 10.1016/j.amjcard.2016.03.018. Epub 2016 Mar 19.

PMID:
27089980
49.

Up-regulation of the mammalian target of rapamycin complex 1 subunit Raptor by aldosterone induces abnormal pulmonary artery smooth muscle cell survival patterns to promote pulmonary arterial hypertension.

Aghamohammadzadeh R, Zhang YY, Stephens TE, Arons E, Zaman P, Polach KJ, Matar M, Yung LM, Yu PB, Bowman FP, Opotowsky AR, Waxman AB, Loscalzo J, Leopold JA, Maron BA.

FASEB J. 2016 Jul;30(7):2511-27. doi: 10.1096/fj.201500042. Epub 2016 Mar 22.

50.

Association of Borderline Pulmonary Hypertension With Mortality and Hospitalization in a Large Patient Cohort: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program.

Maron BA, Hess E, Maddox TM, Opotowsky AR, Tedford RJ, Lahm T, Joynt KE, Kass DJ, Stephens T, Stanislawski MA, Swenson ER, Goldstein RH, Leopold JA, Zamanian RT, Elwing JM, Plomondon ME, Grunwald GK, Barón AE, Rumsfeld JS, Choudhary G.

Circulation. 2016 Mar 29;133(13):1240-8. doi: 10.1161/CIRCULATIONAHA.115.020207. Epub 2016 Feb 12.

Supplemental Content

Loading ...
Support Center